ClinicalTrials.gg
CompletedNCT02761980Updated Dec 7, 2018Results posted

A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers

A Phase 3 interventional study of Ibuprofen 250 mg / Acetaminophen 500 mg and Ibuprofen 250 mg in Fever, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-07.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing ibuprofen in Fever — none open to participants now, none under way, none of them phase 3. Ibuprofen · Fever.

Enrollment
3rd of 18
290 · median 119
Started
2016
the only one that year
Phase 3
6 of 19
none open now
Registered
15th of 19
by date
Lead sponsor
2 of 19
Pfizer

Among the 19 studies testing ibuprofen in Fever, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2016, is one of 6 in phase 3, and was the 15th registered.

Fever

438 studies on the registry are indexed under Fever; 55 are open to participants now.

Browse Fever studies →

Open to participants now

None of the 19 studies testing ibuprofen in Fever is open now. The open studies under Fever, anywhere →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Fever studies recruiting now, 18 (47%) set no upper age limit and 14 (37%) stop at 75 or younger; 22 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing ibuprofen in Fever as a file.
02

Study summary

This is a single dose study that will evaluate the efficacy and safety of a Fixed Dose Combination Ibuprofen 250 mg/ Acetaminophen 500 mg tablet in healthy male patients with fever. Results for the Fixed Dose Combination product will be compared to the individual components Ibuprofen 250 mg and Acetaminophen 500 mg and also compared to placebo.

03

Conditions studied

  • Fever

Browse trials for

Keywords

  • ibuprofen; acetaminophen; induced fever; fever
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects who, at the time of screening, are between 18 and 55 years of age, inclusive. Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead and clinical laboratory tests.
  2. The subject must have a normal, stable body temperature at Screening and on Day 0. If the subject's oral temperature is not between 97.4°F and 98.8°F, then 2 additional oral temperature readings will be obtained within a 30 minute period. These 3 consecutive temperature readings must be between 97.4°F and 98.8°F, with the highest value within 0.4°F of the lowest temperature value.
  3. (BMI) of 17.5 to 37.0 kg/m2; and a total body weight 50 kg (110 lbs) at Screening.
  4. The subject has demonstrably adequate veins, by visual inspection, for IV catheter insertion.

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of laboratory abnormality, hematological, renal, endocrine, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (excluding untreated, asymptomatic, seasonal allergies at the time of dosing) within the last 5 years that may increase the risk associated with study participation.
  2. Subjects with any gastrointestinal disorders (eg, gastrectomy, tracheostomy, esophageal surgeries, short gut syndrome, peptic ulcer disease, known or suspected obstructive disease, previous gastrointestinal surgery, felinization of the esophagus, hypomotility of the gastrointestinal track) that could affect the absorption, metabolism, or excretion of the study medication or affect the results of the ingestible thermometer.
  3. Subjects at risk for excessive bleeding.
  4. Subjects with a history of nasal polyps, angioedema, or significant or actively treated bronchospastic disease.
  5. Screening supine blood pressure ≤90 or ≥140 mm Hg (systolic) or ≤50 or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If blood pressure (BP) is ≤90 or ≥140 mm Hg (systolic) or ≤50 or ≥90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three consecutive BP values should be used to determine the subject's eligibility.
  6. Screening supine 12 lead demonstrating >450 msec or a QRS interval >120 msec at Screening and on Day 1 prior to RSE administration. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three consecutive QTc or QRS values should be used to determine the subject's eligibility.
  7. The subject has a history of recurrent or acute or chronic infections of any type or any findings suggestive of occult infection, such as tuberculosis, sinusitis, urinary tract infection, respiratory tract or dental (abscess) infection, etc., or those with a positive QuantiFERON Tuberculosis, surface antigen, antibody, and/or (HIV) test at Screening. Also excluded are subjects with frequent (more than 3 outbreaks per year), recurrent oral or genital herpes, recurrent herpes zoster, or any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the study.
  8. Subjects who have experienced cold/flu symptoms (ie, runny nose, cough, and/or fever) within 2 weeks prior to the first administration of study treatments.
  9. Subjects with a reduction in heart rate to ≤50 beats per minute or deemed to be at high risk of syncope and/or hypotension per the clinical judgment of the investigator following a carotid sinus massage procedure.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
290 participants (actual)

Study arms

  • Experimental
    Ibuprofen 250 mg / Acetaminophen 500 mg

    Single dose of 2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg by mouth

    Drug: Ibuprofen 250 mg / Acetaminophen 500 mg

  • Active comparator
    Ibuprofen 250 mg

    Single dose of 2 caplets of IBU 125 mg by mouth

    Drug: Ibuprofen 250 mg

  • Active comparator
    Acetaminophen 500 mg

    Single dose of 1 APAP 500 mg caplet + 1 placebo caplet by mouth

    Drug: Acetaminophen 500 mg

  • Placebo comparator
    Placebo

    Single dose of 2 caplets of Placebo by mouth

    Drug: Placebo

Interventions

  • DrugIbuprofen 250 mg / Acetaminophen 500 mg

    Drug page: Ibuprofen

    Ibuprofen 250 mg / Acetaminophen 500 mg

    Also known as: IBU 250 / APAP 500

  • Ibuprofen 250 mg

    Also known as: IBU 250

  • 1 APAP 500 mg caplet

    Also known as: APAP 500

  • DrugPlacebo

    Placebo tablet

06

What researchers measure

Primary outcomes

  1. Time Weighted Sum of Temperature Difference (WSTD) From 0 to 8 Hours

    WSTD 0-8 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 and 8 hours). Temperature difference was defined as baseline temperature (at 0 hour) minus the post-baseline temperature at each time point up to 8 hours (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 and 8 hours).

    Time frame: 0 to 8 hours post-dose

Secondary outcomes

  1. Time Weighted Sum of Temperature Differences (WSTD) From Baseline Through Hours 2, 4 and 6

    WSTD 0-2, 0-4 and 0-6 was defined as time-weighted sum of temperature differences over each specified time interval (0-2 hour, 0-4 hour and 0-6 hour), weighted by time elapsed between each 2 consecutive time points post treatment (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6 hour), within each time interval. Temperature difference was defined as baseline temperature (at 0 hour) minus the post-baseline temperature at each time point within each specified time interval: 1) 0-2 hour (20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes) , 2) 0-4 hour (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4 hour), 3) 0-6 hour (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6 hour).

    Time frame: 0 to 2 hours postdose, 0 to 4 hours postdose, 0 to 6 hours postdose

  2. Time to Return to Normal Body Temperature

    Time to return to normal body temperature was defined as time from initial measurement of normal body temperature (at baseline; before administration of first test dose of RSE to induce pyrexia) till the time at which normal temperature was achieved again after pyrexia. Normal body temperature was defined as the last non-missing body temperature value, assessed prior to or at the time of first RSE test dose.

    Time frame: Baseline (pre-dose) up to 8 hours post dose

  3. Time to Rescue Medication

    Time to rescue medication (other than study treatment) (in minutes) was defined as time from first dosing of study medication to the time a participant first takes a rescue medication, or to the end of the study time for participants that do not take any rescue medication prior to the end of the study. The rescue medication was defined as medication received for the treatment of fever during the time period from the administration of study medication to the time of end of the study.

    Time frame: 0 to 8 hours post dose

  4. Time Weighted Sum of Temperature Difference From 6 to 8 Hours

    WSTD 6-8 was defined as time-weighted sum of temperature differences between 6 to 8 hours post-dose, weighted by time elapsed between each 2 consecutive time points within 6 to 8 hours (6.5, 7, 7.5 and 8 hours). Temperature difference was defined as temperature at 6 hours minus the temperature at specified time points (6.5, 7, 7.5 and 8 hours).

    Time frame: 6 to 8 hours postdose

Other outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug and up to 24 hours after discharge (up to 32 hours) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.

    Time frame: Baseline up to 24 hours after discharge (up to 32 hours)

07

Results

Posted Dec 7, 2018

Participant flow

Participant flow — Overall Study
MilestonePlaceboIbuprofen 250 mg+Acetaminophen 500 mgIbuprofen 250 mgAcetaminophen 500 mg
Started29878787
Completed25808181
Not completed4766
Withdrew: Adverse event4656
Withdrew: Withdrawal by subject0100
Withdrew: Other0010

Outcome measures

PrimaryTime Weighted Sum of Temperature Difference (WSTD) From 0 to 8 Hours

WSTD 0-8 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 and 8 hours). Temperature difference was defined as baseline temperature (at 0 hour) minus the post-baseline temperature at each time point up to 8 hours (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 and 8 hours).

Time frame:
0 to 8 hours post-dose
Reported as:
Mean · degrees fahrenheit
Time Weighted Sum of Temperature Difference (WSTD) From 0 to 8 Hours
degrees fahrenheitPlaceboIbuprofen 250 mg+Acetaminophen 500 mgIbuprofen 250 mgAcetaminophen 500 mg
Time Weighted Sum of Temperature Difference (WSTD) From 0 to 8 Hours9.28 ± 6.39512.54 ± 5.51911.09 ± 6.35512.39 ± 6.278
Statistical analysis
  • Placebo vs Ibuprofen 250 mg+Acetaminophen 500 mg · ANCOVA · p = 0.002 · Lsm difference: 3.14 · 95% CI 1.13 to 5.15
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Ibuprofen 250 mg · ANCOVA · p = 0.210 · Lsm difference: 0.91 · 95% CI -0.52 to 2.33
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Acetaminophen 500 mg · ANCOVA · p = 0.280 · Lsm difference: 0.79 · 95% CI -0.64 to 2.21
  • Placebo vs Ibuprofen 250 mg · ANCOVA · p = 0.030 · Lsm difference: 2.23 · 95% CI 0.22 to 4.25
  • Placebo vs Acetaminophen 500 mg · ANCOVA · p = 0.023 · Lsm difference: 2.35 · 95% CI 0.33 to 4.37
  • Ibuprofen 250 mg vs Acetaminophen 500 mg · ANCOVA · p = 0.864 · Lsm difference: -0.12 · 95% CI -1.54 to 1.29
SecondaryTime Weighted Sum of Temperature Differences (WSTD) From Baseline Through Hours 2, 4 and 6

WSTD 0-2, 0-4 and 0-6 was defined as time-weighted sum of temperature differences over each specified time interval (0-2 hour, 0-4 hour and 0-6 hour), weighted by time elapsed between each 2 consecutive time points post treatment (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6 hour), within each time interval. Temperature difference was defined as baseline temperature (at 0 hour) minus the post-baseline temperature at each time point within each specified time interval: 1) 0-2 hour (20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes) , 2) 0-4 hour (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4 hour), 3) 0-6 hour (10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 minutes, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6 hour).

Time frame:
0 to 2 hours postdose, 0 to 4 hours postdose, 0 to 6 hours postdose
Reported as:
Mean · degrees fahrenheit
Time Weighted Sum of Temperature Differences (WSTD) From Baseline Through Hours 2, 4 and 6
degrees fahrenheitPlaceboIbuprofen 250 mg+Acetaminophen 500 mgIbuprofen 250 mgAcetaminophen 500 mg
WSTD 0-2-0.42 ± 1.8270.48 ± 1.829-0.19 ± 1.8560.21 ± 1.732
WSTD 0-41.79 ± 3.4433.69 ± 3.1522.61 ± 3.3453.41 ± 3.173
WSTD 0-65.26 ± 4.8337.95 ± 4.2456.65 ± 4.7887.65 ± 4.604
Statistical analysis
  • Placebo vs Ibuprofen 250 mg+Acetaminophen 500 mg · ANCOVA · p = 0.004 · Lsm difference: 0.90 · 95% CI 0.29 to 1.51
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Ibuprofen 250 mg · ANCOVA · p = 0.078 · Lsm difference: 0.39 · 95% CI -0.04 to 0.82
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Acetaminophen 500 mg · ANCOVA · p = 0.172 · Lsm difference: 0.30 · 95% CI -0.13 to 0.74
  • Placebo vs Ibuprofen 250 mg · ANCOVA · p = 0.098 · Lsm difference: 0.51 · 95% CI -0.10 to 1.13
  • Placebo vs Acetaminophen 500 mg · ANCOVA · p = 0.054 · Lsm difference: 0.60 · 95% CI -0.01 to 1.21
  • Ibuprofen 250 mg vs Acetaminophen 500 mg · ANCOVA · p = 0.692 · Lsm difference: -0.09 · 95% CI -0.52 to 0.34
  • Placebo vs Ibuprofen 250 mg+Acetaminophen 500 mg · ANCOVA · p = < 0.001 · Lsm difference: 1.87 · 95% CI 0.86 to 2.88
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Ibuprofen 250 mg · ANCOVA · p = 0.094 · Lsm difference: 0.61 · 95% CI -0.10 to 1.33
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Acetaminophen 500 mg · ANCOVA · p = 0.217 · Lsm difference: 0.45 · 95% CI -0.27 to 1.17
  • Placebo vs Ibuprofen 250 mg · ANCOVA · p = 0.015 (Treatment difference and 95 % CI were based on LSM from ANCOVA with treatment, and covariates time from the first RSE full dose to randomization, and baseline temperature.) · Lsm difference: 1.26 · 95% CI 0.24 to 2.27
  • Placebo vs Acetaminophen 500 mg · ANCOVA · p = 0.006 · Lsm difference: 1.42 · 95% CI 0.40 to 2.44
  • Ibuprofen 250 mg vs Acetaminophen 500 mg · ANCOVA · p = 0.659 · Lsm difference: -0.16 · 95% CI -0.87 to 0.55
  • Placebo vs Ibuprofen 250 mg+Acetaminophen 500 mg · ANCOVA · p = < 0.001 · Lsm difference: 2.62 · 95% CI 1.16 to 4.08
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Ibuprofen 250 mg · ANCOVA · p = 0.135 · Lsm difference: 0.79 · 95% CI -0.25 to 1.82
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Acetaminophen 500 mg · ANCOVA · p = 0.186 · Lsm difference: 0.70 · 95% CI -0.34 to 1.74
  • Placebo vs Ibuprofen 250 mg · ANCOVA · p = 0.014 · Lsm difference: 1.83 · 95% CI 0.37 to 3.29
  • Placebo vs Acetaminophen 500 mg · ANCOVA · p = 0.011 · Lsm difference: 1.92 · 95% CI 0.45 to 3.39
  • Ibuprofen 250 mg vs Acetaminophen 500 mg · ANCOVA · p = 0.865 · Lsm difference: -0.09 · 95% CI -1.12 to 0.94
SecondaryTime to Return to Normal Body Temperature

Time to return to normal body temperature was defined as time from initial measurement of normal body temperature (at baseline; before administration of first test dose of RSE to induce pyrexia) till the time at which normal temperature was achieved again after pyrexia. Normal body temperature was defined as the last non-missing body temperature value, assessed prior to or at the time of first RSE test dose.

Time frame:
Baseline (pre-dose) up to 8 hours post dose
Reported as:
Median · minutes
Time to Return to Normal Body Temperature
minutesPlaceboIbuprofen 250 mg+Acetaminophen 500 mgIbuprofen 250 mgAcetaminophen 500 mg
Time to Return to Normal Body Temperature360 (300 to 390)330 (240 to 360)390 (300 to 420)330 (270 to 360)
Statistical analysis
  • Placebo vs Ibuprofen 250 mg+Acetaminophen 500 mg · Log Rank · p = 0.449 (Generalized log-rank test based on interval-censored survival analysis using nonparametric survival method.)
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Ibuprofen 250 mg · Log Rank · p = 0.142 (Generalized log-rank test based on interval-censored survival analysis using nonparametric survival method.)
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Acetaminophen 500 mg · Log Rank · p = 0.822 (Generalized log-rank test based on interval-censored survival analysis using nonparametric survival method.)
  • Placebo vs Ibuprofen 250 mg · Log Rank · p = 0.671 (Generalized log-rank test based on interval-censored survival analysis using nonparametric survival method.)
  • Placebo vs Acetaminophen 500 mg · Log Rank · p = 0.514 (Generalized log-rank test based on interval-censored survival analysis using nonparametric survival method.)
  • Ibuprofen 250 mg vs Acetaminophen 500 mg · Log Rank · p = 0.191 (Generalized log-rank test based on interval-censored survival analysis using nonparametric survival method.)
SecondaryTime to Rescue Medication

Time to rescue medication (other than study treatment) (in minutes) was defined as time from first dosing of study medication to the time a participant first takes a rescue medication, or to the end of the study time for participants that do not take any rescue medication prior to the end of the study. The rescue medication was defined as medication received for the treatment of fever during the time period from the administration of study medication to the time of end of the study.

Time frame:
0 to 8 hours post dose
Reported as:
Median · minutes
Time to Rescue Medication
minutesPlaceboIbuprofen 250 mg+Acetaminophen 500 mgIbuprofen 250 mgAcetaminophen 500 mg
Time to Rescue MedicationNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Ibuprofen 250 mg · hazard ratio · p = 0.997 (P-value, hazard ratio (HR) and corresponding 95% CI were calculated based on the proportional hazards (PH) model with treatment term in the model.)
  • Placebo vs Ibuprofen 250 mg · Hazard Ratio · p = 0.998 (P-value, HR and corresponding 95% CI were calculated based on the PH model with treatment term in the model.)
  • Ibuprofen 250 mg vs Acetaminophen 500 mg · Hazard Ratio · p = 0.997 (P-value, HR and corresponding 95% CI were calculated based on the PH model with treatment term in the model.)
SecondaryTime Weighted Sum of Temperature Difference From 6 to 8 Hours

WSTD 6-8 was defined as time-weighted sum of temperature differences between 6 to 8 hours post-dose, weighted by time elapsed between each 2 consecutive time points within 6 to 8 hours (6.5, 7, 7.5 and 8 hours). Temperature difference was defined as temperature at 6 hours minus the temperature at specified time points (6.5, 7, 7.5 and 8 hours).

Time frame:
6 to 8 hours postdose
Reported as:
Mean · degrees fahrenheit
Time Weighted Sum of Temperature Difference From 6 to 8 Hours
degrees fahrenheitPlaceboIbuprofen 250 mg+Acetaminophen 500 mgIbuprofen 250 mgAcetaminophen 500 mg
Time Weighted Sum of Temperature Difference From 6 to 8 Hours4.96 ± 2.2285.69 ± 1.9045.49 ± 2.2615.84 ± 2.328
Statistical analysis
  • Placebo vs Ibuprofen 250 mg+Acetaminophen 500 mg · ANCOVA · p = 0.101 · Lsm difference: 0.67 · 95% CI -0.13 to 1.48
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Ibuprofen 250 mg · ANCOVA · p = 0.582 · Lsm difference: 0.16 · 95% CI -0.41 to 0.73
  • Ibuprofen 250 mg+Acetaminophen 500 mg vs Acetaminophen 500 mg · ANCOVA · p = 0.614 · Lsm difference: 0.15 · 95% CI -0.43 to 0.72
  • Placebo vs Ibuprofen 250 mg · ANCOVA · p = 0.212 · Lsm difference: 0.51 · 95% CI -0.29 to 1.32
  • Placebo vs Acetaminophen 500 mg · ANCOVA · p = 0.202 · Lsm difference: 0.53 · 95% CI -0.28 to 1.34
  • Ibuprofen 250 mg vs Acetaminophen 500 mg · ANCOVA · p = 0.965 · Lsm difference: -0.01 · 95% CI -0.58 to 0.55
Other pre-specifiedNumber of Participants With Treatment Emergent Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug and up to 24 hours after discharge (up to 32 hours) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.

Time frame:
Baseline up to 24 hours after discharge (up to 32 hours)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs)
ParticipantsPlaceboIbuprofen 250 mg+Acetaminophen 500 mgIbuprofen 250 mgAcetaminophen 500 mg
Number of Participants With Treatment Emergent Adverse Events (AEs)1100

Adverse events

Collected over Baseline up to 24 hours after discharge (up to 32 hours). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/29 (0%)0/29 (0%)1/29 (3.4%)
Ibuprofen 250 mg+Acetaminophen 500 mg0/87 (0%)0/87 (0%)1/87 (1.1%)
Ibuprofen 250 mg0/87 (0%)0/87 (0%)0/87 (0%)
Acetaminophen 500 mg0/87 (0%)0/87 (0%)0/87 (0%)
Most frequent other events
Most frequent other events
EventPlaceboIbuprofen 250 mg+Acetaminophen 500 mgIbuprofen 250 mgAcetaminophen 500 mg
Ear painEar and labyrinth disorders1/290/870/870/87
Rash macularSkin and subcutaneous tissue disorders0/291/870/870/87

Baseline characteristics

Safety analysis set included all participants who received study medication.

Age, Continuous
Age, Continuous(years)PlaceboIbuprofen 250 mg+Acetaminophen 500 mgIbuprofen 250 mgAcetaminophen 500 mgTotal
Mean28.8 ± 7.9733.4 ± 10.5432.3 ± 10.1932.6 ± 9.9932.4 ± 10.07
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIbuprofen 250 mg+Acetaminophen 500 mgIbuprofen 250 mgAcetaminophen 500 mgTotal
Female00000
Male29878787290
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboIbuprofen 250 mg+Acetaminophen 500 mgIbuprofen 250 mgAcetaminophen 500 mgTotal
Hispanic or Latino244313
Not Hispanic or Latino27838384277
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboIbuprofen 250 mg+Acetaminophen 500 mgIbuprofen 250 mgAcetaminophen 500 mgTotal
American Indian or Alaska Native00000
Asian21036
Native Hawaiian or Other Pacific Islander00000
Black or African American510201247
White21726569227
More than one race00000
Unknown or Not Reported142310
08

Study locations

1 site
  • New Orleans Center for Clinical Research
    Knoxville, Tennessee 37920, United States
09

References and documents

Publications

  • Smith W, Leyva R, Kellstein D, Arthur E, Cruz-Rivera M. Efficacy of a Fixed-Dose Combination of Ibuprofen and Acetaminophen Compared With Individual Monocomponents in Adult Male Subjects With Endotoxin-Induced Fever: A Randomized Controlled Trial. Clin Ther. 2021 Jul;43(7):1213-1227. doi: 10.1016/j.clinthera.2021.05.004. Epub 2021 Jul 23. PubMed 34304913 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Dec 2017, 12 months.

Results were first posted in Dec 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2016
First posted
May 4, 2016
StartActual
Dec 6, 2016
Primary completionActual
Dec 6, 2017
CompletionActual
Dec 6, 2017
Results first posted
Dec 7, 2018
Last update
Dec 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02761980
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 4, 2016
Start date
Dec 6, 2016
Primary completion
Dec 6, 2017
Completion
Dec 6, 2017
Results posted
Dec 7, 2018
Last update
Dec 7, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion